Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present data at PAINWeek 2025 regarding the impact of diabetic peripheral neuropathic pain (DPNP) on patients. The presentation, scheduled for September 4, 2025, will showcase insights from a patient survey related to the development of Pilavapadin.
The study focuses on patients' experiences with DPNP despite using current pain relief options. The presentation highlights that diabetic neuropathy affects nearly 50% of diabetes patients during their lifetime, with 25-30% suffering from DPNP specifically, characterized by burning, tingling, and numbness that significantly impacts quality of life.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presenterà dei dati a PAINWeek 2025 sull’impatto del dolore neuropatico periferico diabetico (DPNP) sui pazienti. La presentazione, in programma per il 4 settembre 2025, mostrerà i risultati di un sondaggio condotto tra pazienti coinvolti nello sviluppo di Pilavapadin.
Lo studio si concentra sulle esperienze dei pazienti con DPNP nonostante l’utilizzo delle attuali terapie antidolorifiche. Emergono dati secondo cui la neuropatia diabetica colpisce quasi il 50% dei pazienti diabetici nell’arco della vita e che il 25-30% soffre di DPNP, caratterizzata da bruciore, formicolio e intorpidimento che compromettono significativamente la qualità della vita.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presentará datos en PAINWeek 2025 sobre el impacto del dolor neuropático periférico diabético (DPNP) en los pacientes. La presentación, prevista para el 4 de septiembre de 2025, expondrá hallazgos de una encuesta a pacientes vinculada al desarrollo de Pilavapadin.
El estudio se centra en las vivencias de los pacientes con DPNP pese al uso de las opciones analgésicas actuales. Se destaca que la neuropatía diabética afecta a casi el 50% de las personas con diabetes a lo largo de su vida y que el 25-30% padece DPNP, caracterizada por quemazón, hormigueo y entumecimiento que afectan de forma importante la calidad de vida.
Lexicon Pharmaceuticals (Nasdaq: LXRX)는 PAINWeek 2025에서 당뇨병성 말초 신경병증성 통증(DPNP)이 환자에게 미치는 영향에 관한 데이터를 발표합니다. 발표는 2025년 9월 4일로 예정되어 있으며 Pilavapadin 개발과 관련한 환자 설문조사 결과를 공개할 예정입니다.
이 연구는 현재 사용되는 통증 완화법을 사용하고도 겪는 DPNP 환자들의 경험에 초점을 맞춥니다. 연구 결과에 따르면 당뇨병성 신경병증은 평생 동안 당뇨 환자의 거의 50%에 영향을 미치며, 그중 25~30%가 DPNP를 앓고 있어 작열감, 찌릿함, 무감각 등의 증상이 삶의 질에 큰 영향을 준다고 보고됩니다.
Lexicon Pharmaceuticals (Nasdaq: LXRX) présentera des données à PAINWeek 2025 sur l’impact de la douleur neuropathique périphérique diabétique (DPNP) chez les patients. La présentation, prévue le 4 septembre 2025, exposera les résultats d’une enquête auprès des patients réalisée dans le cadre du développement de Pilavapadin.
L’étude se concentre sur le vécu des patients atteints de DPNP malgré l’utilisation des options actuelles de prise en charge de la douleur. Il en ressort que la neuropathie diabétique touche près de 50 % des patients diabétiques au cours de leur vie et que 25–30 % souffrent de DPNP, caractérisée par des sensations de brûlure, de picotement et d’engourdissement altérant significativement la qualité de vie.
Lexicon Pharmaceuticals (Nasdaq: LXRX) wird auf der PAINWeek 2025 Daten zur Auswirkung diabetischer peripherer neuropathischer Schmerzen (DPNP) bei Patienten vorstellen. Die Präsentation am 4. September 2025 zeigt Erkenntnisse aus einer Patientenbefragung im Zusammenhang mit der Entwicklung von Pilavapadin.
Die Studie beleuchtet die Erfahrungen von Patienten mit DPNP trotz bestehender Schmerztherapien. Hervorgehoben wird, dass diabetische Neuropathie im Laufe des Lebens nahezu 50% der Diabetespatienten betrifft und dass 25–30% von DPNP betroffen sind, die sich durch Brennen, Kribbeln und Taubheitsgefühle auszeichnet und die Lebensqualität erheblich beeinträchtigt.
- None.
- None.
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada.
Presentation details:
- Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin
- Date: September 4, 2025
- Time: 4:00 p.m. – 5:30 p.m. PST
- Location: Exhibit Hall (Level 4)
- Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon Pharmaceuticals
Diabetic neuropathy is a major complication affecting individuals with both type 1 and type 2 diabetes, with nearly half of all patients experiencing it during their lifetime. Among these patients, approximately 25
About Pilavapadin
Discovered using Lexicon’s unique approach to gene science, pilavapadin is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
Pilavapadin has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain (DPNP).
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates, including pilavapadin. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What will Lexicon Pharmaceuticals (LXRX) present at PAINWeek 2025?
How common is diabetic peripheral neuropathic pain among diabetes patients?
Who are the presenters for Lexicon's DPNP study at PAINWeek 2025?
What symptoms characterize diabetic peripheral neuropathic pain according to LXRX's presentation?
